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Recently, microRNAs (miRNAs) are reported to be crucial modulators in the pathogenesis
and potential treatment of epilepsies. To date, several miRNAs have been demonstrated
to be significantly expressed in the epileptic tissues and strongly associated with the
development of epilepsy. Specifically, miRNAs regulate synaptic strength, inflammation,
neuronal and glial function, ion channels, and apoptosis. Furthermore, peripheral blood
miRNAs can also be utilized as diagnostic biomarkers to assess disease risk and
treatment responses. Here, we will summarize the recent available literature regarding the
role of miRNAs in the pathogenesis and treatment of epilepsy. Moreover, we will provide
brief insight into the potential of miRNA as diagnostic biomarkers for early diagnosis and
prognosis of epilepsy.
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INTRODUCTION
Epilepsy is a prevalent chronic neurologic disorder characterized by recurrent unprovoked seizures
due to abnormal neuronal excitability (Hauser and Kurland, 1975). However, there is growing
concern that the pathogenic epilepsy mechanism remains poorly defined. It is estimated that 50
million patients have a diagnosis of epilepsy worldwide with almost 400,000 new cases of epilepsy
diagnosed each year. Unfortunately, one-third of patients are resistant to currently available
antiepileptic drugs (AEDs) that act primarily on the brain to reduce the frequency and severity
of seizures (Perucca et al., 2007). Over the past five decades, there has been a scarcity of novel
treatments that significantly avoid or reverse the development of epilepsy. Therefore, efforts
are currently underway to identify alternative therapeutic approaches that can be utilized either
individually or in combination with other AEDs to drastically improve the morbidity andmortality
associated with epilepsy. Many recent studies have provided evidence for the potential role of
miRNAs in the pathogenesis and treatments of epilepsy. Most of these studies employed animal
models of epilepsy (Liu et al., 2010; Hu et al., 2011, 2012a; Jimenez-Mateos et al., 2011; Song et al.,
2011; McKiernan et al., 2012; Pichardo-Casas et al., 2012; Bot et al., 2013; Risbud and Porter, 2013;
Gorter et al., 2014; Li et al., 2014; Kretschmann et al., 2015), whereas relatively few studies used
human epileptic samples (Kan et al., 2012; McKiernan et al., 2012b; Kaalund et al., 2014; Zucchini
et al., 2014; Wang et al., 2015a,b).
Multiple animal models have been extensively employed to study the pathogenesis and
treatment of epilepsy. These epileptic models can be induced by chemoconvulsants, electrical
stimulation, brain pathology, or genetic engineering. For an in-depth review of animal models
of epilepsy the reader is referred to recent excellent reviews (Löscher, 2011; Kandratavicius
et al., 2014). Experimental models induced by chemoconvulsants, primarily kainic acid (KA) and
pilocarpine, are the most widespread popular and accepted models in the scientific community,
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not only because they are convenient, but also because they
are easy to implement (Leite et al., 2002). These models
are able to evoke both acute and chronic episodes of status
epilepticus (SE) with a latent phase between them. It is worth
to not that experimental model induced either by KA or
pilocarpine is considered more appropriate for TLE studies,
due to their seizure-related neuronal injury and hippocapmal
synaptic reorganization (Lothman and Bertram, 1993; Mathern
et al., 2002). Kindled animals, an electrical stimulated model, are
appropriate for investigating seizure thresholds and therapeutic
responses. It resembles complex partial seizures with secondary
generalization. However, kindling and its relevance to human
epilepsy are still debatable (Bertram, 2007).
Historically, different species have been used for epilepsy
studies such as mice, rats, rabbits, guinea pigs, cats, and dogs.
Compared with other species, rodents (mice and rats) are the
most widely employed species in the field of epilepsy. Specific
similarities and differences results have shown between humans
and each of these species.
MiRNAs are a group of endogenous noncoding ribonucleic
acids (RNA) that mainly function as key modulators of gene
expression at the posttranscriptional level (Pasquinelli, 2012;
Ha and Kim, 2014). Mature miRNAs are able to inhibit
messenger RNA (mRNA) translation and/or promoting mRNA
degradation via binding usually to complementary sequences
within the 3′ untranslated region (3′ UTR) (Lee et al., 1993;
Wightman et al., 1993). However, miRNAs have also been
reported to bind to other positions. Notably, single miRNA can
target several hundred genes and an individual gene can be
targeted by multiple miRNAs. In the last two decades, miRNAs
have fundamentally changed scientists’ understanding of gene
regulatory network (GRN) representing a new interdisciplinary
direction in neuroscience research. To date, several thousands of
miRNAs have been identified as key modulators of various GRN.
Recently, numerous studies have shown that miRNAs regulate a
wide spectrum of brain functions not only in brain development
but also in pathogenic conditions such as epilepsy (Barca-
Mayo and De Pietri Tonelli, 2014). Multiple lines of evidence
indicate that miRNAs participate in the pathogenesis, treatment,
and prevention of epilepsy. They can negatively modulate an
enormous and complex regulatory network of gene expression
levels that govern the process of epilepsy either in experimental
model (Liu et al., 2010; Hu et al., 2011, 2012a; Jimenez-Mateos
et al., 2011; Song et al., 2011; McKiernan et al., 2012; Pichardo-
Casas et al., 2012; Bot et al., 2013; Risbud and Porter, 2013; Gorter
et al., 2014; Li et al., 2014; Kretschmann et al., 2015) or human
epilepsy (Kan et al., 2012; McKiernan et al., 2012b; Kaalund et al.,
2014; Zucchini et al., 2014; Wang et al., 2015a,b). Therefore,
deeper comprehension of the roles, targets, and mechanisms of
miRNAs in the pathogenesis and pathophysiology of epilepsy
will both develop diagnostic biomarkers for epilepsy and identify
promising therapeutic strategies for the development of novel
treatments for epilepsy.
Extensive efforts to get better understanding of miRNA
biology have yielded several publications and databases of
functional miRNA information. In this review, we will focus on
the role of miRNAs regarding their function in the pathogenesis
of epilepsy and summarize the potential utility of miRNA biology
in epilepsy.
BIOLOGY OF miRNAs
MiRNAs comprise species of small endogenous non-coding
RNAs molecules which generally target one or more mRNAs
to control gene expression either by inducing mRNA decay
or reducing its translation. However, miRNAs may positively
modulate mRNA translation through target gene promoter
binding.
It is well-established that mRNA translation is locally
modulated by miRNAs within the synaptodendritic
compartment in response to RICS activity (Im and Kenny,
2012; Aksoy-Aksel et al., 2014). This indicates the spatial-
specificity of expression of the corresponding genes. Of these,
some expressed in particular subcellular compartments, cell
types, and/or neuroanatomical areas playing critical roles in
the brain development and homeostasis (Cao et al., 2006;
Cohen et al., 2011). Alteration of miRNA expression during SE
shows that modulation of miRNAs levels may participate in the
alterations in protein expression during disease progression.
Recent study reported that SE may inhibit synaptoneurosome
miRNAs, which affect the reaction of synapses (Risbud and
Porter, 2013). Moreover, dynamic regulation in the local
miRNAs from brain may be involved in the regulation of
synaptic protein synthesis (Pichardo-Casas et al., 2012).
Exosomes are small secreted lipoprotein vesicles present in
most circulating body fluids, including cerebrospinal fluid (CSF)
and serum (Keller et al., 2006). They are released from various
cells such as dendritic cells and neurons to contribute to cell-
to-cell communication and protein and RNA delivery. In CNS,
exsosomal protein could be used as biomarkers because it can
influence neurons to regulate synaptic scaling and trans-synaptic
propagation of pathogenic processes (Saman et al., 2012). It
is well established that exosomes contain numerous molecular
components of their cell of origin, including mRNAs and
miRNAs. Interestingly, recent evidence points to the bodily fluid-
derived exosomes as a potential source of miRNA biomarkers.
The process of miRNA biogenesis consists of a tightly
controlled multiple steps to generate the mature, functional
form (Figure 1). Typically, miRNAs are transcribed in the
nucleus either form their independent promoters or form introns
which lie within genes encoding proteins. Large numbers of
miRNAs are transcribed mainly by RNA polymerase II (Pol-II)
which generates hairpin structures called primary miRNA (pri-
miRNAs) (Lee et al., 2004). Pri-miRNAs are then processed by
a series of nuclear enzymes cleavage by the nuclease Drosha
microprocessor complex to produce a stem-loop with 60–80 nt
called precursor miRNA (pre-miRNA) hairpin (Lee et al., 2003).
Subsequently, pre-miRNA is transported into the cytoplasm
through exportin-5, importin-β family member, to form the
mature miRNA (19–25 nt) by the RNase III enzyme Dicer
(Hutvágner et al., 2001). It is worthy of note that lack of Dicer is
implicated in various neurological disorders including epilepsy,
neuronal and glial dysfunction, and neurodegeneration (Hébert
et al., 2010; Tao et al., 2011;McKiernan et al., 2012b). To function,
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FIGURE 1 | Overview of miRNA biogenesis and function. miRNAs are transcribed by RNA Pol-II to form a pri-miRNAs which is cleaved by the nuclease Drosha
to produce a pre-miRNA which exports into the cytoplasm to generate mature miRNAs by Dicer. After that, the guide strand of miRNA binds to Ago2 that linked to the
RISC to modulate the translation of target mRNAs, while passenger strand of miRNA is typically degraded.
single strand of the mature miRNA, called the guide strand, is
bound by a member of Argonaute (Ago) proteins family in order
to generate the effector RNA-induced silencing complex (RISC).
The other strand of the mature miRNA, called the passenger
strand, denoted with a star (miR∗) is typically degraded. MiRNA
can then guide the RISC to their target mRNAs by base-pairing
over a minimum 7–8 nt “seed” region of their mRNA targets.
Animal miRNAs are usually complementary to a site within the
3′ UTR. However, miRNAs have also been reported to bind
to the 5′ end and the open reading frame (Bartel, 2009). This
process is followed by supplementary or complementary base
pairing that together control target mRNA specificity and affinity.
This results in translational repression or degradation thereby
decreasing the levels of the target protein ranging from 2- to
10-fold (Fabian et al., 2010). However, miRNAs have also been
reported to promote translation under certain cellular conditions
(Vasudevan et al., 2007).
miRNA ALTERATIONS IN EPILEPSY
Recent works indicated that miRNAs serve pivotal roles in
regulating specific genes expression within neurons (Im and
Kenny, 2012; Aksoy-Aksel et al., 2014). In epilepsy, miRNAs have
been identified as key regulators of protein production during
and following seizures. This suggests that miRNAs may affect
neuronal excitability and remodeling responses. Nudelman et al.
first demonstrated links between altered miRNAs expression and
seizures (Nudelman et al., 2010). They studied expression of
miR-132 in hippocampus of mice 8 h after pilocarpine-induced
SE and found an upregulation in not only level of pri-miR-132
but also in mature miR-132 level. Shortly after, Aronica and
colleagues explored miR-146a expression as well as its cellular
distribution in both animal model and human TLE (Aronica
et al., 2010). The authors found that miR-146a was increased
and persistent in reactive astrocytes, suggested that miR-146a
is implicated in the controlling of the astroglial inflammatory
response occurring in TLE.
miRNA Regulation Following SE
The first study about miRNA profiles after SE was by Liu
and colleagues. They profiled miRNA expression alterations
following KA in rats and detected a significant overlap
between the expression of miRNA and mRNA, particularly
in gene expression, immunological response, and cell death
processes (Liu et al., 2010). The authors found 8 miRNAs were
significantly deregulated in both brain tissue and blood samples.
Subsequently, multiple studies profiled miRNA responses in the
brain using different models, different seizure durations, different
time points and different platforms, suggested that miRNAs may
play an important role in pathogenesis of epilepsy (Hu et al.,
2011, 2012a; Jimenez-Mateos et al., 2011; Song et al., 2011;
McKiernan et al., 2012; Pichardo-Casas et al., 2012; Bot et al.,
2013; Risbud and Porter, 2013; Gorter et al., 2014; Li et al.,
2014; Kretschmann et al., 2015). miRNAs expression Profiles
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were performed on the lithium-pilocarpine model (Hu et al.,
2011, 2012a; Song et al., 2011), systemic pilocarpine (Risbud
and Porter, 2013), systemic KA (Liu et al., 2010; McKiernan
et al., 2012; Pichardo-Casas et al., 2012), intra-amygdala KA
(Jimenez-Mateos et al., 2011), electrical stimulation of angular
bundle (Gorter et al., 2014), electrical stimulation of amygdala
(Bot et al., 2013; Li et al., 2014), or pilocarpine and self-sustained
SE (Kretschmann et al., 2015), with time points ranging from a
few hours (McKiernan et al., 2012) to 4 months after induction of
SE (Gorter et al., 2014), making direct comparisons difficult. It is
worthy of note that a subset of miRNAs is specifically associated
with epilepsy includemiR-146a, -10b, -34a, -132, -125b, -155, -21,
-134, -34c-5p, -212-3p, -219, -218, -204, -184, -98, -381, -181b,c, -
221, -222, -196, Let-7i, -9, -23a, -423-3p, -30c, -375, -497, -450a,
-296-5p, let-7b, -374, -137, -124, and -199, all of which have been
supported by at least two fully independent studies. However,
other sets of miRNAs were dysregulated in some studies, but
not in others. These variances may be due to varied standards
or criteria for the model selection of SE. Furthermore, varied
standards to identify significantly dysregulated miRNAs can also
result in varied outcomes. Hippocampus is composed of several
subfields that have vastly different molecular and functional
characterization (Lein, 2004; Greene et al., 2009). Thus, analyzing
miRNA expression in tissues obtained from different subfields
may lead to different results. Moreover, different species, models,
size of samples, brain areas, phases of the disease, array platforms,
study design, technical factors, and extraneous effects may also
influence the profiling of miRNA abundance.
In 2014, Gorter et al. used Exiqon microRNA arrays to assess
the profile of miRNA expression changes in cornu ammonis
area 1 (CA1), dentate gyrus (DG) and parahippocampal cortex
(PHC), at 1 day, 1 week, and 3–4 months after SE (Gorter
et al., 2014). In CA1 and DG, more increased than decreased
miRNAs were observed in each phase following SE with highest
increased miRNAs in the chronic phase in the DG, while in
PHC, most of miRNAs were downregulated. More recently,
Kretschmann et al. compared miRNA expression patterns in the
whole hippocampus using one acute seizure model evoked by
electrical stimulation and two chronic epilepsy models induced
either by pilocarpine or self-sustained SE (Kretschmann et al.,
2015). Among those screened, an overlap of three miRNAs,
miR-30a-5p, miR-142-5p, and miR-331-3p, between the acute
and chronic models was reported. Although the three miRNAs
were significantly expressed, only miR-142-5p was consistently
upregulated in both acute and chronic models. Table 1 provides a
summary of the differentially expressed miRNAs in experimental
models of epilepsy.
In the brain, endogenous programs of neuroprotection
can be elicited by exposure to brief, non-harmful seizures
(preconditioning), which is considered as a potential means
to protect against epilepsy (Jimenez-Mateos and Henshall,
2009). Two previous studies undertook miRNA expression
profiling at two different time points in experimental models
of epileptic tolerance: after seizure preconditioning but before
SE (McKiernan et al., 2012) and after SE in previously
preconditioned mice (Jimenez-Mateos et al., 2011). In response
to SE, most of expressed miRNAs were upregulated, this
was drastically reduced in the tolerance mice, in which
only 18% of the expressed miRNAs were upregulated and
82% were downregulated (Jimenez-Mateos et al., 2011). This
indicates that genomic responses to SE are reprogrammed by
seizure-preconditioning, which was also observed for protein
coding genes in preconditioning-induced ischemic tolerance
(Stenzel-Poore et al., 2007). It has been found that epileptic
tolerance features transcriptional suppression due to increasing
miRNA levels by preconditioning seizures that would later
decrease mRNAs of protein-coding genes (Jimenez-Mateos et al.,
2008). In the cornu ammonis area 1 (CA3) subfield of the
mouse hippocampus, seizure preconditioning upregulated levels
of 25 mature miRNAs with the greatest upregulation detected for
miR-184, whereas no miRNA was significantly down-regulated
(McKiernan et al., 2012).
miRNA Regulation in Human Epilepsy
In the intervening years, six studies have undertaken the miRNA
expression profiling either in brain tissue samples (Kan et al.,
2012; McKiernan et al., 2012b; Kaalund et al., 2014; Zucchini
et al., 2014) or serum (Wang et al., 2015a,b) of patients with
epilepsy (Table 2), along with study on individual miRNAs in
human epilepsy (Aronica et al., 2010; Jimenez-Mateos et al.,
2012; Omran et al., 2012; Ashhab et al., 2013a,b; Peng et al.,
2013; Alsharafi and Xiao, 2015). Specifically, miRNAs expression
profiles were performed on patients with mesial temporal lobe
epilepsy (mTLE) (Kan et al., 2012; Kaalund et al., 2014),
temporal lobe epilepsy (TLE) (McKiernan et al., 2012b), or
Drug-resistant epilepsy (Zucchini et al., 2014; Wang et al.,
2015b). Each study provided a new insight into the potential
functions of miRNAs in the pathogenesis of human epilepsy.
The first study was conducted by Kan et al. (2012). In their
study, human hippocampal tissues either with or without
sclerosis were analyzed to profile human miRNA. The authors
found that 51 miRNAs were significantly dysregulated. Several
of these miRNAs were decreased in neuron and increased
in glia, others were highly expressed in the nucleus which
suggested a novel function of these miRNAs or a defect in their
biogenesis. Furthermore, astrocytes and the immune response
can be regulated by differentially expressed miRNAs in mTLE
(Kan et al., 2012). Widespread reduction of mature miRNAs in
patients with mTLE was reported by McKiernan and co-workers.
They indicated that miRNA were collapsed as an extra patho-
mechanism in mTLE due to loss of Dicer expression which was
reduced in this study (McKiernan et al., 2012b).
In a recent study, more than 1000 human miRNAs were
profiled in 14 human hippocampi obtained from patients with
intractable TLE and hippocampal sclerosis (HS) either with type-
2 granule cell pathology in 7 cases or with no granule cell
pathology in the other 7 cases. They found that, 6 miRNAs were
increased and 6 miRNAs were decreased as well. Of these, miR-
487a was validated using qPCR and ANTXR1 was identified as a
probable target.
In another study, miRNA expression profiling demonstrated
that 30 miRNAs were statistically expressed in biopsy specimens
obtained from patients with mTLE/HS (Kaalund et al., 2014).
Of these, miR-218 and miR-204 were statistically decreased
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TABLE 1 | miRNA profiling in experimental model.
Model Stage (Time point) Platform Aberrantly expressed miRNAs Regulation References
KA SzPc (mouse) Acute (8 h) TaqMan miR-148b, -376a, -335, -9, -129, -132, -34c, -369-3p, -204,
-299-5p, -30a-3p, -7, -34b, -409-5p, -29a, -100, -184, -448, -28,
-140, -29c, -375, -31, -130b, let-7f
Up McKiernan et al., 2012
KA (rat) Acute (24 h) TaqMan miR-298 Up Liu et al., 2010
miR-155, -29c, -34b-3p, -98, -122, -203, -450a Down
PILO (rat) Acute (24 h) Microarray
(Agilent)
miR-213, -132, -30c, -26a, -375, -99a, -24, -124a, -22, -34a,
-125a, -101-1, -29b, -125b, -199a, -196b, -150, -151, -145
Up Hu et al., 2011
miR-29a, -181c, -215, -181b, -25, -10b, -21 Down
KA SzPc (mouse) Acute (24 h) Taqman miR-10b, -21, -29a, -30e, -125a, -132, -134, -139, -146b, -153,
-181c, -199a, -219, -323, -328, -375, -425, -451, -487b, -507,
-509, -518d, -532
Up Jimenez-Mateos et al.,
2011
miR-27a, -101, -103, -107, -127, -133b, -145, -148b, -200a,
-326, -330, -374, -381, -422b, -497, -520b, -657
Down
KA SzPc (mouse) Acute (24 h) Taqman miR-10b, -21, -27a -29a, -30e, -101, -103, -107, -125a, -127,
-132,-134, -139, -145, -146b, -148b, -153, -181c, -199a, -200a,
-219, -323, -326, -328, -375, -425, -451, -487b, -507, -509,
-518d, -532, -629
Up Jimenez-Mateos et al.,
2011
miR-133b, -330, -374, -381, -422b, -497, -520b, -657 Down
PILO (mouse) Acute (24 h) Microarray
(Exiqon)
miR-2137, -21-5p, -711, -212-3p, -882, -1947-5p, -21-3p,
-142-5p, -467d-5p, -132-3p, -710, -712-5p, -223-3p, -142-3p,
-706, -691, -294-5p, -709, -22-3p, -29a-3p, -431-5p, -126-3p,
-29b-1-5p, -483-3p, -29b-3p, -1892, -1957, let-7a-5p, -23a-3p,
let-7e-5p, -1935, -19a-3p, -494-3p, -24-2-5p, -335-3p,
-146b-5p, -203-3p, -875-3p, -1983, -1897-5p, -17-5p, -146a-5p,
-1895, -290-5p, -674-5p
Up Kretschmann et al.,
2015
miR-331-3p, let-7d-3p, -181c-5p, -324-5p, let-7b-3p, -194-5p,
-409-5p, -125b-2-3p, -1941-3p, -467d-3p, -433-3p, -30a-5p,
-149-5p, -668-3p, -873-5p, -181d-5p, -467e-5p, -181b-5p,
-466d-3p, -761, -1839-3p, -124-5p, -186-5p, -224-5p,
-218-2-3p, -881-3p, -330-5p, -491-5p, -337-5p, -380-3p,
-542-3p, -361-5p, -181a-1-3p, -669h-3p, -449b, -1224-5p,
-374-5p/, -374c-5p, -466c-5p, -208a-3p, -425-3p, -466g,
-760-3p, -673-5p, -301b-3p, -742-3p, -488-5p, -216b-5p,
-499-5p, -1b-5p, -211-5p, -703, -339-3p, -466l-3p, -302b-5p
Down
ES (rat) (7–90 d) Microarray
(Exiqon)
miR-212-3p, -132-3p, -21-5p, -132-5p, -212-5p, -146a-5p,
-23a-3p, -370-5p
Up Bot et al., 2013
miR-344b-2-3p,-345-5p, -322-5p, -124-5p, -291a-5p, -7a-2-3p,
-138-2-3p, -330-3p, -128-3p, -664-3p, -383-5p, -29b-2-5p,
-7a-1-3p, -205, -1843-3p, -497-5p, -29c-3p, -7b, -138-1-3p,
-505-3p, -30a-3p, -1843-5p, -743a-5p, -186-5p, -103-3p,
-324-5p, -324-3p, -124-3p, -330-5p, -582-5p, -107-3p,
-146b-5p, -148b-3p, -335, -301a-3p, -29a-5p, -30b-5p, -935,
-130a-3p, -190a-5p, -31a-5p, -3580-3p, -29c-5p, -9b-5p,
-26a-5p, -218a-5p, -137-3p, -708-5p, -101a-3p, -30a-5p,
-33-5p, -30d-5p, -139-5p, -374-5p, -30e-5p, -7a-5p, -551b-3p,
-187-3p
Down
ES (rat) Latent (7 d) Microarray
(Exiqon)
miR-21-5p*, -212-3p, -132-3p, -370-5p* Up Bot et al., 2013
miR-7a-2-3p, let-7d-3p, -1843-5p, -1843-5p, -124-3p, -301a-3p,
-324-5p, -29a-5p, -708-5p, -935, -92b-3p, -374-5p*, -328a-3p,
-139-5p, -30d-5p, -33-5p* -187-3p*, -551b-3p, -7a-5p
Down
PILO (mouse) Chronic (28 d) Microarray
(Exiqon)
miR-135b-5p, -132-3p, -199a-5p, -23a-3p, -129-5p, -129-2-3p,
-669c-5p, -467e-5p, -212-3p, -203-3p, -467c-3p, -467e-3p,
-455-3p, -466f-3p, -669f-3p, -222-3p, -297c-5p, -27a-3p,
-297a-5p, -467g, -22-5p, -494-3p
Up Kretschmann et al.,
2015
(Continued)
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TABLE 1 | Continued
Model Stage (Time point) Platform Aberrantly expressed miRNAs Regulation References
miR-325-3p, -345-5p, -1949, let-7f-1-3p, -191-5p, -350-3p,
-331-3p, -875-3p, -138-1-3p, -181a-5p, -34b-3p, -409-5p,
-338-5p, -676-3p, -187-3p, -551b-3p, -674-5p, -194-5p,
-324-5p, let-7d-3p, -210-3p, -140-3p, -298-5p, -130a-3p,
-29b-1-5p, -92b-3p, -330-3p, -431-3p, -767
Down
ES (rat) Chronic (30 d) Microarray
(Exiqon)
miR-146a-5p, -132-5p, -21-5p*, -212-5p, -23a-3p, -34a-5p,
-370-5p*, -34b-5p, -24-2-5p, -433-3p, -34c-5p
Up Bot et al., 2013
miR-29c-5p, -30a-5p, -374-5p*, -33-5p*, -218a-5p, -187-3p*,
-30e-5p, -352, -29b-3p
Down
PILO (rat) Chronic (60 d) Microarray
(µParaflo)
miR-99a, -134, -127, -379, -137, -324-5p, -27b, -383, -132, -24,
-29a, -139-5p, -9*, -23b, -146a, -140*, -23a, -126
Up Song et al., 2011
miR-98, -352, let-7e, -185, let-7d Down
PILO (rat) Chronic (60 d) Microarray
(Agilent)
miR-146a, -211, -203, -210, -152, -31, -23a, -34a, -27a Up Hu et al., 2012a
miR-138, -301a, -136, -153, -19a, -135b, -325-5p, -380, -190,
-542-3p, -33, -144, -542-5p, -543, -296
Down
ES (rat) Chronic (60 d) NGS miR-455-3p, -345-3p, -423-3p, -54, -365-5p, Up Li et al., 2014
miR-296-5p Down
ES (rat) Chronic (3–4m) Microarray
(Exiqon)
miR-126, -126*, -129, -129-2*, -132, -132*, -135a, -140, -140*,
-143, -144, -145, -146a, -152, -199a-3p, -199a-5p, -204, -21,
-210, -212, -212*, -214, -223, -23a, -23b, -24, -24-1*, -24-2*,
-27a, -27b, -322, -34a, -34b, -34c, -378, -451, -542-3p
Up Gorter et al., 2014
miR-139-5p, -187, -218a, -551b, -935 Down
PILO (rat) Acute (4 h) Microarray
(Exicon)
miR-132, -184, -214, -516b, -470, -518c*, -519e*, -519c-5p,
-503, -M1-4, -583, -BART8*, -637, -M1-8, -K12-6-3p, -S1-5p,
-713, -658, -K12-8, -467b*, -132*, -934, -125b-1*, -193a-5p,
-21*, -185*, -183*, miRPlus_27560, -423-5p, -711-765,
Plus_28431, -675-5p, -498, -883a-5p, -149*, Plus_42487,
-516a-5p, -miR-881*, -212, -885-3p, -483-5p, -642, -485-3p,
-625*, -30c-2*, -371-5p, Plus_42745, -187*, -921, Plus_42793,
-300*, -638, -882, ebv-miR-BHRF1-1, -25*, -193b*, -300, -763,
-294*, -518a-5p, -551a, -198, -204*
Up Risbud and Porter,
2013
ND Down
PILO (rat) Acute (48 h) Microarray
(Exicon)
miR-21, -155, -M1-8, -685, -S1-5p, -_SNORD3@, -881*,
-483-5p, Plus_42793, -300
Up Risbud and Porter,
2013
miR-9, -126, let-7i, -130a, let-7d, -103, -107, -125a-5p -137,
-148a -154, -181b, -191, -181a* -218, -22, -221, -222, -26a,
-299-5p, -29b -29c, -30a,-376b, -377, -382, -378, -503, -519d,
-519e, -98, -99b, -207, -300, -30e*, -329, -345-5p, -380-3p,
-433*, -434-3p, -434-5p, -151-5p, -333, -336, -352, -450a,
-7-1*, U6-snRNA-1, -138, -301a, -369-5p, -195, -322, -10a,
-376a*, -539, -487b, -541, -29c*, -361-5p, -374b, -381, -664,
-124, -411, -7-2*, -30b, -629*, -691, -92b, -let-7a, -let-7d, -let-7f,
-let-7a*, miRPlus_17891, -99b*, -491-3p, -186, -450a, -let-7c,
-let-7i, -100, -148b, -30a*, -let-7g, -742, -374a, -190, -139-5p,
-363*, -744, -891a, -30e, -872, -741, -667, -let-7b, -9*, -768-5p,
-340, -125b, -804, -384-3p, -342-3p, let-7f, -126*, -505, -382*,
-376c*, -598, let-7e, let-7g, -485-5p, -181c, -136*, -22*, -933,
-494, -589, -379*, -26b, -384, -634, -503*, -376c, -140-3p, -145,
let-7c-1*, -505, -337-3p, -328, -495, -136*, -325, -99a, -887,
-33a, -34b, -668, -138, let-7e* -872*, -665, -347, -125b*, -411*,
-337-3p, -29b-2*, -582-5p, -150,-149, -218-2*, -597, -888*,
-127-3p, -28-5p, -181d, -384-5p, -497, -433, miRPlus_42856,
-743b, -181a, -337-5p, -138-1*, -331-3p, -875-3p, -379*, -467e*,
-124*, -185, -327, -551b, -29a*, -30c, -409-5p, -582-3p, -134,
-BART17-5p, -101b, -323-3p, -742,
Down
(Continued)
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TABLE 1 | Continued
Model Stage (Time point) Platform Aberrantly expressed miRNAs Regulation References
PILO (rat) Latent (3w) Microarray
(Exicon)
miR-21, -142-3p, -155, -19a, -19b, -583, -BART8*, -685, -S1-5p,
-K12-8, -193a-5p, Plus_17952, _SNORD2, -142-5p, -675-5p,
-498, Plus_42487, -516a-5p, -20b, -106a, -20a, -17, -423-3p,
-371-5p, -20b, -25*, -550, -34a
Up Risbud and Porter,
2013
miR-299-5p, -7-1*, -615-3p Down
PILO (rat) Acute (2 h) qPCR miR-124, -134, -132,-21, -183, -135a, -125b, -27a, -9, -155, 30c Up Omran et al., 2012;
Ashhab et al.,
2013a,b; Peng et al.,
2013; Alsharafi and
Xiao, 2015
miR-221, -222, -138, -181a, -128 Down
Latent (3w) miR-132, -146a, -27a Up
miR-21, -221, -222, 30c Down
Chronic (60 d) miR-124, -134, -132,-21, -183, -135a, -125b, 27a, -9, -146a,
-155, -181a, -30c
Up
miR-138, -221,- 222, -128 Down
PILO, pilocarpine; KA, kainic acid; SE, status epilepticus; ES, Electrical stimulation; NGS, next-generation sequencing; SzPc, seizure preconditioning; ND, not detected. *means the
passenger strand of the mature miRNA.
TABLE 2 | miRNA profile in human epilepsy.
Patients Specimen Platform Aberrantly expressed NAs Regulation References
mTLE Hippo Microarray
(Exiqon)
miR-9, let-7f, -16, -17, -20a, -26b, -27a, -92b, -99a, -106a,
-126, -129-3p, -135a, -190, -193a-3p, -195, -203, -301a,
-340, -362-3p, -374a, -374b, -597, -625, -660, -1297
Up Kan et al., 2012
miR-141, -146b-3p, -185,-214, -220c, -490-3p, -635, -637,
-642, -665, -920, -934, -1255a, -1304, -1469, -1973,
Plus-F1021, Plus-E1026, Plus-E1185, Plus-E1212,
Plus-E1232
Down
TLE Hippo/TL
neocortex
Taqman miR-133b, -182, -200c, -650, -380-5p, -594, -223, -501,
-203, -451
Up McKiernan et al., 2012b
miR-181d, -130b-3p, let-7g, -411-5p, -335-5p, -210,
-103a-3p, -23b-3p, let-7d, -25-3p, -340, -100-5p, -99a-5p,
-27b-3p, -126-5p, -324-5p, -21-5p, -425, -92, -497-5p,
-125b-5p, let-7f-5p, -187, -330-3p, -29c, -423, -130a-3p,
-433, -95, let-7b-5p, -30d-5p, -106b-5p, -9*, -301a-3p,
-30b-5p, -432-5p
Down
DRE HGC Microarray
(Agilent)
miR-1234, -1281, -30c-1*, -92b, -191*, -1238 Up Zucchini et al., 2014
miR-3607-5p, -219-5p, -338-3p, -590-5p, -487a, -3659 Down
mTLE Hippo Microarray
(Exiqon)
miR-302b, -432*, -299-3p, -501, -515-3p, -197, -502, -383,
-183, -519d, -493, -338-5p, -10b, -184, -141, -375, -200a,
-130b, -182, -193b, -361, -368, -519e*, -429, -199a,
Up Kaalund et al., 2014
miR-140*, -204, -211, -490, -218 Down
Epilepsy Serum NGS
(Illumina)
miR-144-5p, -15a-5p, -181c-5p, -194-5p, -889-3p, -96 Up Wang et al., 2015a
let-7d-5p, -106b-5p, -130a-3p, -146a-5p Down
DRE Serum NGS
(Illumina)
miR-574-5p, -67, novel -9 Up Wang et al., 2015b
miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p,
-3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p, novel-451
Down
mTLE Hippo qPCR miR-183, -135a, -125b, -27a, -146a, -155, -9, 181a, 124,
134, -21, -132, -30c,
Up Omran et al., 2012; Ashhab
et al., 2013a,b; Peng et al.,
2013; Alsharafi and Xiao,
2015
miR-128, -138, -221, -222 Down
mTLE, mesial temporal lobe epilepsy; DRE, drug resistant epilepsy; Hippo, hippocampus; T.L., temporal lobe; HGC, hippocampal granule cells; NGS, next-generation sequencing.
*means the passenger strand of the mature miRNA.
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TABLE 3 | Common differentially expressed miRNAs.
Human studies/experimental models Upregulated miRNAs Downregulated miRNAs
Experimental models miR-17, -21-5p, -23a/b, -24, -24-2-5p, -27b, -31,
-34a/c, -125a, -129, -132, -132*, -140, -142-3p/5p,
-146a, -148, -152, -184, -199a, -204, 212-3p/5p, -214,
233, -296, -375, -451, -455-3p, -711, -882
Let-7d-5p/3p, let-7f, -29c-3p/5p, -30a-5p, -30e-5p, -34b-3p, -92b,
-98, -124-5p, -130a-3p, -138, -181a/b/d, -185, -186, -187, -190,
-191, -218a, -301a-3p, -325, -330-3p/5p, 331-3p, 337-5p,
-345-5p, -361-5p, -374-5p, -380-3p, -381, -409, -450, -497, -505,
-551b-3p, -582-5p, -664, -742, -875-3p, -935
Human epilepsy miR-9, -27a, -92b, -130a-3p, -135a, -141, -182, -183,
-203, -501
let-7d-5p, -30b-5p, -106b-5p, -204, -301a-3p, -490
The Let-7d-5p, miR-92b, miR-130a-3p, miR-204, and miR-301a-3p were expressed in both experimental models and human epilepsy, which are highlighted. *means the passenger
strand of the mature miRNA.
in mTLE/HS, and both were highly expressed in the different
hippocampal subfields. Meanwhile, miR-204 and miR-218
expressions were dynamically altered during hippocampal
development in pigs. Taken together, these findings indicate
that both miR-204 and miR-218 may play a pivotal role in the
molecular mechanisms involved in the progression of pathology
in mTLE/HS (Kaalund et al., 2014). Surprisingly, the most
hippocampus-enriched miRNAs (let-7 family, miR-9 and miR-
124) were not detected in most of epilepsy studies (Eacker et al.,
2011; Shinohara et al., 2011). Thus, it requires researchers in the
field of epilepsy to re-mine their previous data to identify the
underlying mechanisms.
Comparison of Experimental to Human
Epilepsy
There are multiple challenges to overcome in order to
successfully compare such outcomes. First, different miRNAs
have different expression patterns in different tissues and models
(Pichardo-Casas et al., 2012). This means that comparing the
miRNA expression pattern between animal models and human
epilepsy is unreliable. Second, different miRNAs varies with
phase of disease. Avoiding comparison between different phases
of epilepsy in animal models is therefore a significant challenge
to overcome. Specifically, only deregulated miRNAs in chronic
phase of epilepsy in animal models can be compared with
the expression levels of those miRNAs deregulated in human
epilepsy. Third, different miRNAs varies with ethnicity and age.
This means that data obtained from immature animal model and
children with epilepsy cannot be compared with those obtained
from adults. In addition, different patient race studies cannot
be compared as well. Finally, the comparison is also challenging
due to the discrepancies among the different criteria (i.e., 1.5-
vs. 2.0-fold of changes) used to select the differentially expressed
miRNAs in these profiling studies. These outstanding obstacles
still make a direct comparison difficult. Therefore, compare data
with similar methodology, model, species, tissues, phase, and
race may lead to more reliable outcomes. However, no perfect
agreements in the literature about miRNAs comparison rules
have been provided.
In this section, we attempted only to connect recent available
profiling studies to highlight the similarities and differences in
the miRNAs found altered in animal models and human with
epilepsy.
The miRNA expression levels were considered to be selected
only if they met the following criteria: (i) validating in at
least 2 profiling studies; (ii) showing no expression variation
or discrepancies in all previously reported datasets. According
to these criteria, we observed that there is an overlap between
these previously reported datasets. We found that 75 miRNAs
(43 downregulated and 32 upregulated) fulfilled all the criteria
in animal models. In human epilepsy, only 16 miRNAs met our
criteria, 6 downregulated and 10 upregulated miRANs as well
(Table 3). Of these, downregulation of let-7d-5p and miR-301a-
3p levels were corroborated between animal models and human
epilepsy studies. Likewise, miR-92b andmiR-130a-3p were found
to be upregulated in human epilepsy but were downregulated
in animal model of epilepsy, while miR-204 was found to be
downregulated in human epilepsy and upregulated in animal
models. Interestingly, all these 5 miRNAs were found to be
deregulated in the chronic phase of epilepsy in animal models,
which make our comparison meaningful. Therefore, these 5
miRNAs may play different roles, individually or in combination,
in the pathogenesis and treatment of epilepsy. However, further
studies on these miRNAs are required to identify the underlying
mechanisms.
Among different research groups, multiple dramatic
discrepancies were observed regarding the expression of
miRNAs during epilepsy. Some of these discrepancies were
definitely due to variations in the methodology, while most
of these discrepancies were a mystery. For example, in animal
profiling studies, we found clear discrepancies in the expressions
of miR-126, -19a, -99a, -378, -153, and -137 that may arise from
the difference in phases of epilepsy. Likewise, discrepancies
in the expression of miR-324-5p, -210, let-7e, -153 and -181c
could be related with differences in the species being employed,
while discrepancies in miR-181c, -153 -155, -542-3p, and -203
expressions might be related with differences in the model
being used. On the other hand, there were clear unexplained
discrepancies for miR-21, 27a, -29a, -34b, -124, -134, -139-5p, -
145, and -99a expressions. Notably, these miRNAs are found to
be expressed in most studies.
In human epilepsy, we observed that miR-340 expression was
upregulated in the tissues obtained from patients with mTLE
in a microarray profiling study (Kan et al., 2012), whereas
downregulated expression was reported in tissues obtained from
TLE patients in a profiling study using Taqman array (McKiernan
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et al., 2012b). Therefore, the difference of tissues and array
platforms might explain the discrepancies. The expression of
miR-146a was upregulated in tissues obtained from children
with mTLE using qPCR (Omran et al., 2012), but when next-
generation sequencing (NGS) platform was used its expression
was downregulated in serum obtained from adult patients with
epilepsy (Wang et al., 2015a). For miR-141, no any variations
were reported which may explain the discrepancies.
Up to now, problems are recognized in the interpretation
of results from expression profiling studies of human brain
specimens. First, the majority of studies have employed tissues
that were obtained either from autopsies or epileptic tissue
is derived from surgery specimens and normal tissue from
autopsies. Second, post-mortem modifications and durations
have found to vastly change the molecular constituents of
the obtained tissue, making the data questionable. Finally,
different regions in the brain have different cellular constituents
that definitely alter in the course of diseases. Therefore,
researchers should reconsider their methodology to overcome
these challenges.
miRNAs AS BIOMARKERS OF EPILEPSY
To date, epilepsy diagnosis is based mainly on EEG and
neuroimaging, which appear at comparatively late phases in the
pathogenesis. These methods are not only expensive but also
do not provide high-resolution data sets. This urges the need
for noninvasive, easy detected, sensitive and specific biomarkers
to improve the current diagnosis and to predict the treatment
outcome of epilepsy. Owing to chemistry of miRNAs, stability
in biofluids and resistance to nuclease digestion in plasma,
serum, CSF, and other bodily fluids (Chen et al., 2012; Boon
and Vickers, 2013), they have emerged as potential biomarkers of
many neurological disease states, including Parkinson’s disease
(Shtilbans and Henchcliffe, 2012), multiple sclerosis (Gandhi
et al., 2013), Alzheimer’s disease (Tan et al., 2014), and epilepsy
(Wang et al., 2015a,b). In epilepsy, most of the available
target and genome-wide miRNA expression profiling studies
were based on animal or human hippocampal tissues. Only
few profiling studies have focused on the use of miRNAs as
biomarkers. Liu et al., in their brilliant study, showed that three
miRNAs (miR-333, -685, and -298) were dysregulated at 24 h
after KA-induced SE in whole-blood miRNA expression profile,
indicating that these three miRNAs can be considered to be
used as diagnostic biomarkers for epilepsy (Liu et al., 2010). In
a study by You et al., increased miR-196b were reported as a
novel biomarker for the diagnosis and prediction of epilepsy
associated with glioma (You et al., 2012). In our previous study,
we observed that miR-34a, -22, -125a, and -21 were significantly
deregulated in hippocampal tissues as well as in rat peripheral
blood at 24 h following SE, representing a role for these miRNAs
in the future diagnosis of epilepsy (Hu et al., 2011). Significant
alterations of miR-21 expression were also found at latent phase
which was coincided with the change observed in other brain
areas (Gorter et al., 2014). Gorter et al. examined the expression
levels of miR-21, -146a, and -142, in plasma at different phases
of TLE (Gorter et al., 2014). The upregulation of miR-146a
expression in plasma appeared comparatively later in the chronic
phase, while miR-142 was increased during the acute phase.
Recently, circulatory miRNA expression profiling have provided
valuable molecular markers for detection of epilepsy (Wang
et al., 2015a,b). Wang and co-workers used Illumina HiSeq 2000
technology to profile the genome-wide miRNA expression in
serum from 30 patients with epilepsy (partial and generalized)
(Wang et al., 2015a) and 30 patients with drug-resistant epilepsy
(Wang et al., 2015b). In the former study, According to their
criteria (fold-change >2.0 or <-2.0; p < 0.05; miRNA copies ≥
10), 6 down-regulated miRNAs and 4 up-regulated miRNAs were
reported. Among these 10 dysregulated miRNA, 4 miRNAs (Let-
7d-5p, miR-106b-5p, -130a-3p, and -146a-5p) were significantly
upregulated, and 2 miRNAs (miR-15a-5p and -194-5p) were
significantly decreased in human epilepsy relative to normal
controls. Moreover, miR-106b-5p was considered as the best
diagnostic biomarker for epilepsy due to its high sensitivity and
specificity. In the latter study, 12 miRNAs were found decreased
and 3 were found increased in drug-resistant patients relative
to drug-responsive group. Following miRNAs confirmation by
qRT-PCR, miR-194-5p, miR-301a-3p, miR-30b-5p, miR-342-
5p, and miR-4446-3p were statistically dysregulated in drug
resistant group when compared to drug-responsive patients and
control group. Of these 5 miRNAs, miR-301a-3p was reported
as the best diagnostic biomarker for drug-resistant epilepsy
with highest sensitivity and specificity. Interestingly, this miRNA
was significantly correlated with seizure severity in a direct
negative manner. Notably, miR-301a-3p and miR-106b-5p were
also reported to be downregulated in hippocampal tissues of
patients with TLE (McKiernan et al., 2012b). Therefore, both
are not only potential diagnostic biomarkers but also may play
a neuroprotective role during TLE.
Interestingly, exosomes represent another important source
of miRNA as a biomarker. Various exosomal proteins have
been reported as critical biomarkers in a variety of neurological
diseases such as Alzheimer disease, Parkinson’s disease, prion
disease, and glioblastoma (Rajendran et al., 2006; Vella et al.,
2007; Skog et al., 2008; Alvarez-Erviti et al., 2011). Hu et al. and
co-workers observed that miR-29b can be released in exosomes
to control HIV which is associated with attenuated platelet-
derived neurotrophic factor (PDGF) in adjacent neurons (Hu
et al., 2012b). Therefore, exosomes carried genetic information
have potential clinical utility for biomarkers tools.
THERAPEUTIC ASPECTS OF miRNAs
Since alterations in miRNA expression profiles have been
observed after SE in experimental epilepsy models (Liu et al.,
2010; Hu et al., 2011, 2012a; Jimenez-Mateos et al., 2011; Song
et al., 2011; McKiernan et al., 2012; Pichardo-Casas et al., 2012;
Bot et al., 2013; Risbud and Porter, 2013; Gorter et al., 2014; Li
et al., 2014; Kretschmann et al., 2015) and in patients with TLE
(Kan et al., 2012; McKiernan et al., 2012b; Kaalund et al., 2014;
Zucchini et al., 2014; Wang et al., 2015a,b), a subset of miRNAs
are under investigation as potential regulators of a wide variety
pathways involved in epilepsy such as neuroinflammation,
blood brain barrier (BBB) dysfunctions, apoptosis, ion channels,
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tumors, axonal guidance, cell proliferations, neuronal function,
and synaptic plasticity (Chen et al., 2007; Friedman et al., 2007;
Delaloy et al., 2010; Magill et al., 2010; Smrt et al., 2010; Zhao
et al., 2010; Tivnan et al., 2011; Iyer et al., 2012; Sano et al., 2012;
Henshall, 2013; Shaltiel et al., 2013; Dombkowski et al., 2014;
Jiang et al., 2014; Lopez-Ramirez et al., 2014; Zheng et al., 2014;
Haenisch et al., 2015; Kamphuis et al., 2015; Rom et al., 2015;
Xiang et al., 2015) (Table 4).
Two direct strategies to develop miRNA-based therapeutics
were identified: mimics or agomirs to restore a loss of function
of miRNAs and increase their effective levels. The other called
inhibitors or antagomirs which intended to block endogenous
levels of miRNAs to increase expression of its mRNA targets.
Several functional studies using agomirs/antagomirs reported
miRNAs as novel potential approaches to treat epilepsy. For
instance, antagonizing miR-132 significantly decreased the
hippocampal damage, indicating that miR-132 overexpression
may play a role in neuronal death during SE (Jimenez-Mateos
et al., 2011). miR-132 modulates hippocampal mRNAs such as
acetylcholinesterase (AChE) or the GTPase activator p250GAP
(Hanin and Soreq, 2011; Shaltiel et al., 2013). In addition, miR-
132 has been previously linked to synaptic plasticity (Vo et al.,
2005; Wayman et al., 2008). In contrast, antagonizing miR-184
enhanced cell injury after preconditioning by KA (McKiernan
et al., 2012). This suggests that miR-184 may serve to enhance
cell survival post-SE. In another study, antagomirs against miR-
134 markedly reduced spine density on pyramidal neurons in
CA3 and suppressed seizure severity after intra-amygdala KA
injection (Jimenez-Mateos et al., 2012). Moreover, the miR-134
antagomirs prevented KA toxicity in vitro in a Limk1-dependent
manner. This indicates that targeting of miR-134 may also be a
promising direct neuroprotective and not as simple as it might
seem.
It is well-established that neuronal injury after seizures
results in direct excitotoxic necrosis. For example, miR-34a has
been found to directly target p53, suggesting a proapoptotic
TABLE 4 | miRNA involved in epilepsy and possible targets.
miRNA Regulation Targets Related pathways to epilepsy References
146a Up IL-1β Inflammation Aronica et al., 2010; Iyer et al., 2012; Omran et al., 2012
221, 222 Down ICAM1 Inflammation Kan et al., 2012; Ashhab et al., 2013a
155 Up TNF-α Inflammation, BBB Ashhab et al., 2013b; Lopez-Ramirez et al., 2014;
Kamphuis et al., 2015
98 Down CCL2, CCL5 Inflammation, BBB Rom et al., 2015
34a Up Bcl-2, Caspase-3,
TSC1 3′ UTR
Apoptosis, Neuronal differentiation, and
synaptic signal transmission
Tivnan et al., 2011; Hu et al., 2012a; Sano et al., 2012;
Henshall, 2013; Dombkowski et al., 2014
423-3p Up Caspase-3,
Caspase-6
Apoptosis Li et al., 2014
296-5p Down Caspase-3 Apoptosis Li et al., 2014
132 Up CREB, AChE,
BDNF/TrkB
Dendritic growth, arborization, cholinergic tone,
and calcium channel
Friedman et al., 2007; Fabian et al., 2010; Magill et al.,
2010; Shaltiel et al., 2013; Xiang et al., 2015
134 Up Limk1 Dendritic spine Jimenez-Mateos et al., 2012
487a Down ANTXR1 Granule cell dispersion Zucchini et al., 2014
219 Down CaMKIIγ NMDA receptor Zheng et al., 2014
218 Down GRM1, SLC1A2,
ROBO1, GNAI2
Axonal guidance and synaptic plasticity Kaalund et al., 2014
204 Down GRMI Axonal guidance and synaptic plasticity Kaalund et al., 2014
23a Up TSC1 3′ UTR Synaptic signal transmission and remodeling Song et al., 2011; Dombkowski et al., 2014
21 Up NT-3 Neurite outgrowth Risbud and Porter, 2013
Let-7i Up Unknown Neuronal death Chen et al., 2007
184 Up AKT2 Apoptosis, Interleukin signaling, and cell
proliferation
Krichevsky et al., 2006; McKiernan et al., 2012
9 Up Unknown Nerve regeneration, epilepsy Network, cell
proliferation, cell migration, and neural
differentiation
Krichevsky et al., 2006; Delaloy et al., 2010
196b Up PCNA Cell proliferation You et al., 2012
let-7b Up Nuclear receptor
TLX
Cell proliferation Liu et al., 2010; Zhao et al., 2010
137 Up Ubiquitin ligase
mind bomb-1
Neuronal maturation Smrt et al., 2010
124 Up Unknown Neural differentiation and cell proliferation Peng et al., 2013
199 Down HIF-1α Neuronal cell death and angiogenesis Jiang et al., 2014
212-3p, 132-3p Down SOX11 Neural differentiation and neuronal excitability Haenisch et al., 2015
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effect of this miRNA in cells (Hermeking, 2010). In our
previous work, we found that antagonizing miR-34a after intra-
cerebroventricular injection of pilocarpine in rats attenuated
the expression of activated caspase-3 by targeting bcl-2. We
suggested that miR-34a may participate in promoting neuronal
survival and reduce neuronal death or apoptosis (Hu et al.,
2012a). However, Sano et al. did not find any of these
effects of miR-34a after intra-amygdala injection of KA in
mice (Sano et al., 2012). Other studies also observed that
miR-34a participates in regulating neuronal differentiation and
synaptic signal transmission (Tivnan et al., 2011; Sano et al.,
2012; Henshall, 2013; Dombkowski et al., 2014). The different
results may be due to the varied animal models employed
and varied time points analyzed. In a recent study, miR-219
was found to be downregulated in the hippocampus at days
1, 3, 7, and 10 after intra-cerebroventricular injection of KA.
In the same study, silencing of miR-219 by its antagomir
led to seizure behaviors, abnormal cortical EEG recordings.
Meanwhile, treatments with the miR-219 agomir suppressed
seizures and abnormal EEG recordings. The authors provided
evidence that in miR-219 play a pivotal role in ameliorating
epilepsy via regulating the CaMKII/NMDA receptor pathway
(Zheng et al., 2014). In fact, the mechanism of miRNA
hypofunction by antagomirs is based on its molecular chemistry
via mediating the degradation and sequestration mechanisms
(Stenvang et al., 2012). These results suggest antagomirs/agomir
targeting these miRNAmay represent novel approach to epilepsy
treatment.
Increasing evidence has shown that miRNAs play a
universal role in neuro-inflammation which contributes to
the development of the epileptogenic process (Vezzani and
Granata, 2005; Vezzani et al., 2013). Related researches were
aimed to evaluate the role of inflammation-related miRNAs in
epilepsy. Omran et al. examined the correlation between the
expression of IL-1β and miR-146a in immature rats and children
with mTLE. The authors found that both IL-1β and miR-146a are
upregulated and variable depending on the disease phase (Omran
et al., 2012). In a previous study, it was claimed thatmiR-146a was
linked to astrocyte-mediated inflammatory response (Iyer et al.,
2012). Ashhab and colleagues aimed to detect the relationship
between TNF-α and proinflammatory miR-155 in immature
rats and children with mTLE (Ashhab et al., 2013b). They found
that these two markers had similar expression patterns in the
three phases of mTLE development, which were upregulated
in the seizure-related phases but not in the seizure-free phases.
The co-expression of TNF-α and miR-155 in astrocyte indicates
a direct correlation during mTLE development (Ashhab et al.,
2013b). In 2012, miR-221 and miR-222 were also found to target
ICAM1 in astrocyte level in patients with mTLE, suggesting
a potential role of these inflammation-related in mTLE (Kan
et al., 2012). In 2013, Ashhab and colleagues aimed to explore
the dynamic expression of miR-221 and miR-222 in the three
phases of TLE and in children with TLE. They demonstrated
that both miR-221 and miR-222 were downregulated in the three
phases of TLE in animal models and in children with epilepsy
(Ashhab et al., 2013a). In the same study, inflammation-related
miR-138 was decreased in the seizure-related phase but not in
the latent phase, whereas inflammation-related miR-181a was
decreased in the acute phase, normal in the latent phase and
increased in the chronic phase (Ashhab et al., 2013a). In our
previous work, we investigated the dynamic expression pattern
of inflammation-related miR-128, miR-30c, and miR-27a in
the three phases of TLE as well as in patients with TLE. We
found that miR-128 was downregulated in the acute and chronic
phase, while in the latent phase no changes were observed. For
miR-30c, upregulation expression was found in the acute and
chronic phases and downregulation expression was found in the
latent phase of TLE, whereas miR-27a was upregulated in the
three phases of TLE. In TLE patients, miR-30c and miR-27a were
upregulated, whereas miR-128 was downregulated. These studies
not only support the role of inflammation in epilepsy but also
provide evidence that modulation of these inflammation-related
miRNAs may be a new target for AEDs.
Brain-specific and brain-enriched miRNAs represent
promising targets for experimental and therapeutic modulation.
Brain-specific miR-124, miR-134, and miR-9 were significantly
increased in the seizures related phases (acute and chronic
phases), but not in the seizure-free phases (latent phase) in
immature rats after SE (Ashhab et al., 2013a; Peng et al., 2013).
In the same studies, miR-124, miR-134, and miR-9 were also
upregulated in children with mTLE that indicate their possible
roles in the treatment of epilepsy in the developing brains. MiR-9
was also implicated in nerve regeneration, epilepsy network,
cell proliferation, cell migration, and neural differentiation
(Krichevsky et al., 2006; Delaloy et al., 2010). However, further
studies are required to determine whether targeting this
interesting miRNA by its agomir/antagomir colud affect seizure
variables. In our previous study, we revealed upregulation of
brain-specific miR-183 andmiR-135a as well as of brain-enriched
miR-125b in the seizure-related phases and TLE patients but
not in the seizure-free phases, suggesting that all may provide
a potential therapeutic approach for the treatment of TLE
(Alsharafi and Xiao, 2015).
Overexpression of miR-196b has been implicated in pre-
operative seizures in patients with glioma, and might be a
valuable tool to predict seizure prognosis in patients without
pre-operative seizures (You et al., 2012). Therefore, targeting
this valuable miRNA may be a new therapeutic approach. Let-
7b has also been implicated in regulating neural stem cell
proliferation and differentiation by inhibiting nuclear receptor
TLX signaling (Zhao et al., 2010). Other miRNAs such as miR-
137 and miR-199 have also been implicated in epilepsy (Hu
et al., 2011; Jimenez-Mateos et al., 2011; Song et al., 2011;
Risbud and Porter, 2013) as well as in regulating neuronal
functions (Smrt et al., 2010; Jiang et al., 2014). miR-132-3p
and 212-3p have been reported to target SOX11 and contribute
to regulate neuronal function as well as neuronal excitability
(Haenisch et al., 2015). These finding indicate that modulation
of above-mentioned miRNAs, individually or in combination,
may exert neuroprotective and disease-modifying effects in
epilepsy.
Unfortunately, the BBB potentially restricts the entry of
beneficial drugs for treatment of CNS disorders. It is estimated
that almost 98% of small molecule drugs fail to cross the BBB,
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whereas large molecule drugs are unable to cross the BBB. Several
strategies have previously been investigated for enabling drugs to
across the BBB include chemical and biological delivery systems,
BBB disruption, molecular Trojan horses, and particulate drug
carrier systems. On the other hand, BBB dysfunction was found
to be during epilepsy.
Interestingly, there is growing evidence that endogenous
miRNAs can modulate the function of BBB. For instance, several
miRNAs including miR-15a, -18b, -26a, -27a/b, -30a/b/c/d/e, -31,
-106b, -125a-5p, -155, -195, and -487b were found to increase
BBB function in patients with multiple sclerosis (Kamphuis
et al., 2015). In a recent study by Lopez-Ramirez et al.,
miR-155 was also found to negatively regulate BBB under
neuroinflammatory conditions (Lopez-Ramirez et al., 2014).
More recently, Rom et al. reported that miR-98 and let-
7g∗ contribute to protect the BBB during neuroinflammatory
disorders (Rom et al., 2015). Interestingly, several reports have
proved that miR-98 is downregulated in the acute and chronic
phases of TLE in rats (Liu et al., 2010; Song et al., 2011;
Risbud and Porter, 2013). Since neuroinflammation have been
found to play a critical role in the pathogenesis of human
epilepsy (Vezzani and Granata, 2005; Vezzani et al., 2013),
these BBB-associated miRNA may also contribute to protect
the BBB function during epilepsy. Therefore, modulating of
these miRNAs may be a promising strategy to overcome BBB
challenges.
CONCLUDING REMARKS
It is evident that miRNAs dysregulation can occur as a
result of epilepsy. The previous profiling studies provide new
insights into the molecular mechanisms associated with the
disease progression. miRNA are involved in neuroprotection,
CNS development, dendritic spines, neuronal differentiation,
and synaptic signal transmission. Moreover, miRNAs may play
special roles in regulating a set of genes associated with a wide
range of pathways in the pathogenesis of epilepsy. Thus, a deeper
understanding of these biological processes can lead to novel
diagnostic and therapeutic strategies. Preclinical studies have
shown that pathways such as the Bcl-2, IL-1β, NT-3 and the
MAPK pathway that are also involved in miRNA dysregulation
may also be promising new horizons for diagnosis and treatment
of experimental as well as clinical epilepsy. However, further
validations are actively needed.
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